Value proposition

a leader in the development of comprehensive solutions for cardiovascular regenerative therapies

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its CardiAMPTM and CardiALLOTM therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells.

These programs are enabled by the Company's HelixTM transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.